Opinion|Podcasts|May 2, 2024

Exploring Procedural Treatments for Dry Eye

Listen

0:00 / 0:00

Experts discuss treating dry eye with procedural therapies, focusing on common in-office and at-home treatments.

1:00 Dry eye evaluation

4:00 Dry eye practice

9:00 Initial exam and tests

17:00 Choosing a procedure

25:00 Dry eye procedures

37:00 Creating treatment value

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to HCPLive today.

Related to this article

October 7th, 2026

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

October 7th, 2026

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

October 7th, 2026

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

October 7th, 2026

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

October 6th, 2026

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

October 6th, 2026

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

October 6th, 2026

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

October 6th, 2026

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.